<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03600285</url>
  </required_header>
  <id_info>
    <org_study_id>TB/TB1K-001</org_study_id>
    <nct_id>NCT03600285</nct_id>
  </id_info>
  <brief_title>Prospective, Single-Arm, Study to Assess the Safety and Performance of the TB1-K Device for Organ Preservation in Donor Kidneys for Transplantation</brief_title>
  <acronym>EMERGE</acronym>
  <official_title>Prospective, Single-Arm, Study to Assess the Safety and Performance of the TB1-K Device for Organ Preservation in Donor Kidneys for Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transplant Biomedicals, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transplant Biomedicals, S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TB1-K Device is an organ preservation and transportation system, using ultrasound technology&#xD;
      with a cooling system to preserve the organ in optimal conditions during transport to the&#xD;
      transplant recipient.&#xD;
&#xD;
      This is a prospective, single-arm, multi-center study comparing to a historical control for&#xD;
      cold storage.&#xD;
&#xD;
      The study is conducted in accordance with the Standard ISO 14155 (Clinical investigation of&#xD;
      medical devices for human subjects - Good clinical practice), and other legal requirements.&#xD;
&#xD;
      The study objective is to assess the safety and performance of the TB1-K device in donor&#xD;
      kidneys intended for transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">February 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of DGF</measure>
    <time_frame>1 week after transplant</time_frame>
    <description>Rate of delayed graft function (DGF), defined as need for dialysis in the first week after transplant, once hyperacute rejection, vascular and urinary tract complications are ruled out.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Kidney Preservation and Transportation</condition>
  <arm_group>
    <arm_group_label>TB1-K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TB1-K preservation arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TB1-K</intervention_name>
    <description>Use of TB1-K for preservation and transport of donated kidneys</description>
    <arm_group_label>TB1-K</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Donor Inclusion Criteria:&#xD;
&#xD;
          1. Donor kidney suitable for preservation&#xD;
&#xD;
          2. Only one kidney per donor will be included&#xD;
&#xD;
          3. Cold ischemia time (CIT) ≤ 24 hours&#xD;
&#xD;
          4. Donor age over 18 years old&#xD;
&#xD;
          5. Donor meets one of the following:&#xD;
&#xD;
               1. Donor after brain death (DBD), standard and extended criteria&#xD;
&#xD;
               2. Donor after circulatory death (DCD), cardiac arrest Maastricht classification III&#xD;
                  (awaiting cardiac arrest, controlled)&#xD;
&#xD;
          6. Signed written informed consent&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          1. Kidney, which investigator is unwilling to use, or presence of moderate or severe&#xD;
             traumatic kidney injury, or anatomical kidney vascular abnormalities, which would&#xD;
             preclude the organ from being acceptable by the transplant surgeon&#xD;
&#xD;
          2. Donor after circulatory death (DCD), Maastricht classification I, II, IV, V (See&#xD;
             Definitions, section 14)&#xD;
&#xD;
          3. Living donors&#xD;
&#xD;
          4. Previous usage of a perfusion machine (PM)&#xD;
&#xD;
          5. Kidneys not considered suitable for preservations&#xD;
&#xD;
          6. Positive serology (HIV, Hepatitis B surface antigen &amp; C)&#xD;
&#xD;
        Recipient Inclusion Criteria:&#xD;
&#xD;
          1. Registered primary kidney transplant candidate, male or female&#xD;
&#xD;
          2. Age ≥ 18 years old&#xD;
&#xD;
          3. Signed written informed consent&#xD;
&#xD;
        Recipient Exclusion Criteria:&#xD;
&#xD;
          1. Prior solid organ or bone marrow transplant&#xD;
&#xD;
          2. Multi-organ transplant&#xD;
&#xD;
          3. Active malignancy&#xD;
&#xD;
          4. Active infection&#xD;
&#xD;
          5. Pregnant females, females intending to get pregnant, or not willing to use a secure&#xD;
             contraceptive method.&#xD;
&#xD;
          6. Participation in another clinical trial.&#xD;
&#xD;
          7. Patient with known donor-specific HLA antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fritz Diekmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i provincial de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Unviersitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <state>Hospitalet De Llobregat</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VIVIAN</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

